中外医学研究Issue(25)：1-2,3,3.DOI:10.14033/j.cnki.cfmr.2015.25.001
重组组织型纤溶酶原激活剂静脉溶栓治疗脑梗死的作用观察
Effect Observation on Travenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator on Treating Acute Cerebral Infarction
徐振华 1颜伟健 1邓宇1
作者信息
- 1. 邵阳医学高等专科学校附属医院 湖南 邵阳 422000
- 折叠
摘要
Abstract
Objective:To investigate the effect of Recombinant Tissue-type Plasminogen Activator(rt-PA) thrombolytic therapy cerebral function and safety.Method:From January 2012 to June 2014 admitted to our hospital the incidence <3 h 44 patients with acute cerebral infarction were randomly divided into two groups,thrombolysis thrombolysis group received rt-PA thrombolytic therapy, the control group used Aspirin therapy.Comparing thrombolysis group and the control group of patients with acute cerebral infarction treatment after different treatments,and in the pre-treatment and post-treatment of patients with neurological deficit scores.Assess the safety of thrombolysis in patients,including symptoms of bleeding,revascularization occlusion.Result:After treatment,the treatment significantly improved compared with NIHSS scores(P<0.05),7 d thrombolytic therapy group than in the control group improved more significantly(P<0.01).Symptomatic hemorrhage,vascular occlusion of two groups,there were no significant difference(P>0.05).Conclusion:The incidence of acute cerebral infarction <3 h using rt-PA thrombolytic therapy has a good therapeutic effect,and better security.关键词
重组组织型纤溶酶原激活剂/急性脑梗死/静脉溶栓/神经功能缺损Key words
Recombinant Tissue-type Plasminogen Activator/Acute cerebral infarction/Intravenous thrombolysis/Neurological deficit分类
医药卫生引用本文复制引用
徐振华,颜伟健,邓宇..重组组织型纤溶酶原激活剂静脉溶栓治疗脑梗死的作用观察[J].中外医学研究,2015,(25):1-2,3,3.
